Literature DB >> 21190462

Rosiglitazone, PPARγ, and type 2 diabetes.

Barbara B Kahn1, Timothy E McGraw.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21190462      PMCID： PMC3733169          DOI： 10.1056/NEJMcibr1012075

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  6 in total

Review 1.  New drugs for the treatment of diabetes mellitus: part I: Thiazolidinediones and their evolving cardiovascular implications.

Authors:  Darren K McGuire; Silvio E Inzucchi
Journal:  Circulation       Date:  2008-01-22       Impact factor: 29.690

Review 2.  Therapeutic targets to reduce cardiovascular disease in type 2 diabetes.

Authors:  Cyrus DeSouza; Vivian Fonseca
Journal:  Nat Rev Drug Discov       Date:  2009-05       Impact factor: 84.694

3.  Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence.

Authors:  James P Boyle; Theodore J Thompson; Edward W Gregg; Lawrence E Barker; David F Williamson
Journal:  Popul Health Metr       Date:  2010-10-22

4.  Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5.

Authors:  Jang Hyun Choi; Alexander S Banks; Jennifer L Estall; Shingo Kajimura; Pontus Boström; Dina Laznik; Jorge L Ruas; Michael J Chalmers; Theodore M Kamenecka; Matthias Blüher; Patrick R Griffin; Bruce M Spiegelman
Journal:  Nature       Date:  2010-07-22       Impact factor: 49.962

5.  Covalent peroxisome proliferator-activated receptor gamma adduction by nitro-fatty acids: selective ligand activity and anti-diabetic signaling actions.

Authors:  Francisco J Schopfer; Marsha P Cole; Alison L Groeger; Chen-Shan Chen; Nicholas K H Khoo; Steven R Woodcock; Franca Golin-Bisello; U Nkiru Motanya; Yong Li; Jifeng Zhang; Minerva T Garcia-Barrio; Tanja K Rudolph; Volker Rudolph; Gustavo Bonacci; Paul R S Baker; H Eric Xu; Carlos I Batthyany; Y Eugene Chen; Tina M Hallis; Bruce A Freeman
Journal:  J Biol Chem       Date:  2010-01-22       Impact factor: 5.157

Review 6.  Adipose tissue as an endocrine organ.

Authors:  Sandra Galic; Jon S Oakhill; Gregory R Steinberg
Journal:  Mol Cell Endocrinol       Date:  2009-08-31       Impact factor: 4.102
  6 in total
  25 in total

1.  Protein sets define disease states and predict in vivo effects of drug treatment.

Authors:  David Meierhofer; Christopher Weidner; Ludger Hartmann; Johannes A Mayr; Chung-Ting Han; Frank C Schroeder; Sascha Sauer
Journal:  Mol Cell Proteomics       Date:  2013-04-11       Impact factor: 5.911

2.  Ligand and receptor dynamics contribute to the mechanism of graded PPARγ agonism.

Authors:  Travis S Hughes; Michael J Chalmers; Scott Novick; Dana S Kuruvilla; Mi Ra Chang; Theodore M Kamenecka; Mark Rance; Bruce A Johnson; Thomas P Burris; Patrick R Griffin; Douglas J Kojetin
Journal:  Structure       Date:  2012-01-11       Impact factor: 5.006

3.  Cancer-preventive rexinoid modulates neutral lipid contents of mammary epithelial cells through a peroxisome proliferator-activated receptor γ-dependent mechanism.

Authors:  Iván P Uray; Jennifer M Rodenberg; Reid P Bissonnette; Powel H Brown; Michael A Mancini
Journal:  Mol Pharmacol       Date:  2011-11-03       Impact factor: 4.436

4.  G Protein-coupled Receptor 40 (GPR40) and Peroxisome Proliferator-activated Receptor γ (PPARγ): AN INTEGRATED TWO-RECEPTOR SIGNALING PATHWAY.

Authors:  Shuibang Wang; Keytam S Awad; Jason M Elinoff; Edward J Dougherty; Gabriela A Ferreyra; Jennifer Y Wang; Rongman Cai; Junfeng Sun; Anetta Ptasinska; Robert L Danner
Journal:  J Biol Chem       Date:  2015-06-23       Impact factor: 5.157

Review 5.  Emerging role of tumor cell plasticity in modifying therapeutic response.

Authors:  Siyuan Qin; Jingwen Jiang; Yi Lu; Edouard C Nice; Canhua Huang; Jian Zhang; Weifeng He
Journal:  Signal Transduct Target Ther       Date:  2020-10-07

Review 6.  Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes.

Authors:  Raymond E Soccio; Eric R Chen; Mitchell A Lazar
Journal:  Cell Metab       Date:  2014-09-18       Impact factor: 27.287

Review 7.  Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects.

Authors:  Robert S Rosenson; R Scott Wright; Michael Farkouh; Jorge Plutzky
Journal:  Am Heart J       Date:  2012-10-16       Impact factor: 4.749

8.  Identification of a mitochondrial target of thiazolidinedione insulin sensitizers (mTOT)--relationship to newly identified mitochondrial pyruvate carrier proteins.

Authors:  Jerry R Colca; William G McDonald; Gregory S Cavey; Serena L Cole; Danielle D Holewa; Angela S Brightwell-Conrad; Cindy L Wolfe; Jean S Wheeler; Kristin R Coulter; Peter M Kilkuskie; Elena Gracheva; Yulia Korshunova; Michelle Trusgnich; Robert Karr; Sandra E Wiley; Ajit S Divakaruni; Anne N Murphy; Patrick A Vigueira; Brian N Finck; Rolf F Kletzien
Journal:  PLoS One       Date:  2013-05-15       Impact factor: 3.240

9.  Effects of Sulfonylureas on Peroxisome Proliferator-Activated Receptor γ Activity and on Glucose Uptake by Thiazolidinediones.

Authors:  Kyeong Won Lee; Yun Hyi Ku; Min Kim; Byung Yong Ahn; Sung Soo Chung; Kyong Soo Park
Journal:  Diabetes Metab J       Date:  2011-08-31       Impact factor: 5.376

10.  Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation.

Authors:  Jang Hyun Choi; Alexander S Banks; Theodore M Kamenecka; Scott A Busby; Michael J Chalmers; Naresh Kumar; Dana S Kuruvilla; Youseung Shin; Yuanjun He; John B Bruning; David P Marciano; Michael D Cameron; Dina Laznik; Michael J Jurczak; Stephan C Schürer; Dušica Vidović; Gerald I Shulman; Bruce M Spiegelman; Patrick R Griffin
Journal:  Nature       Date:  2011-09-04       Impact factor: 49.962
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.